**Core Concept**
Sugammadex is a selective relaxant binding agent (SRBA) used to reverse neuromuscular blockade caused by rocuronium and vecuronium, two commonly used non-depolarizing muscle relaxants. It works by encapsulating the neuromuscular blocking agent, preventing its action and facilitating its elimination.

**Why the Correct Answer is Right**
Sugammadex is the first SRBA approved for clinical use. It selectively binds to rocuronium and vecuronium, preventing them from interacting with nicotinic acetylcholine receptors on the muscle surface. This results in the reversal of neuromuscular blockade, allowing for rapid recovery of muscle function. The selective binding mechanism of sugammadex minimizes the risk of side effects and allows for a more precise reversal of neuromuscular blockade.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not correct as sugammadex is not used for reversal of depolarizing muscle relaxants like succinylcholine.
* **Option B:** This option is not correct as sugammadex is not a competitive antagonist of neuromuscular blocking agents; it works by encapsulation rather than competing for receptor binding.
* **Option C:** This option is not correct as sugammadex is not used to enhance the action of neuromuscular blocking agents; it is used to reverse their effects.

**Clinical Pearl / High-Yield Fact**
Sugammadex is a valuable tool in the management of patients undergoing surgery, particularly those requiring rapid reversal of neuromuscular blockade to facilitate extubation and recovery. Its selective binding mechanism and rapid onset of action make it an attractive alternative to traditional reversal agents like neostigmine.

**Correct Answer: C. Reversal of neuromuscular blockade caused by rocuronium and vecuronium.**